Methods for modulating hematopoiesis and vascular growth
First Claim
Patent Images
1. A method of stimulating a population of undifferentiated mesodermally derived cells to undergo at least one of hematopoiesis and vascular growth;
- comprising;
(a) selecting a compound that is functionally equivalent to a gene product expressed in an embryo'"'"'s extraembryonic tissue;
(b) causing the compound to access the cells, so as to stimulate the cells to undergo at least one hematopoiesis and vascular growth.
1 Assignment
0 Petitions
Accused Products
Abstract
This application pertains to methods and compositions that modulate proliferation and/or differentiation of undifferentiated mesodermally-derived cells so as to have an effect on at least one of vascular growth and hematopoiesis.
-
Citations
56 Claims
-
1. A method of stimulating a population of undifferentiated mesodermally derived cells to undergo at least one of hematopoiesis and vascular growth;
- comprising;
(a) selecting a compound that is functionally equivalent to a gene product expressed in an embryo'"'"'s extraembryonic tissue;
(b) causing the compound to access the cells, so as to stimulate the cells to undergo at least one hematopoiesis and vascular growth. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- comprising;
-
27. A method of treating developmental errors in vascular growth or hematopoiesis in an embryo in utero, comprising:
-
(a) selecting an effective dose of a compound that is functionally equivalent to a gene product expressed in an extraembryonic tissue; and
(b) causing the compound to access a population of embryonic cells in vivo, so as to stimulate the cells to undergo at least one of hematopoiesis and vascular growth. - View Dependent Claims (28, 29, 30)
-
-
31. A method of treating a subject suffering from an abnormal number of erythroid cells, comprising:
-
(a) selecting an effective dose of a compound that is functionally equivalent to a gene product expressed in an extraembryonic tissue; and
(b) causing the compound to access a population of hematopoietic stem cells over an effective time so as to modulate the number of cells undergoing at least one of proliferation or hematopoiesis. - View Dependent Claims (32, 33, 34, 35, 36, 37, 39, 42)
-
-
38. A method of treating a subject suffering from an ischemia in tissues, comprising:
-
(a) selecting an effective dose of a compound that is functionally equivalent to a gene product expressed in an extraembryonic tissue; and
(b) administering the compound to the ischemic site over an effective time so as to stimulate vascular growth within the ischemic tissues. - View Dependent Claims (40, 41)
-
-
43. A method of treating abnormally enhanced vascular growth in a subject, comprising:
-
(a) selecting an effective dose of a hedgehog compound capable of inhibiting the activity of a gene product expressed in an extraembryonic tissue; and
(b) administering the compound to the subject over an effective time so as to inhibit abnormally enhanced vascular growth.
-
-
44. An in vitro assay for determining the activity of a compound capable of modulating hematopoiesis or vascular growth, comprising:
-
(a) selecting a population of cells from a tissue derived from a fertilized egg of a mammal, wherein the population of cells is deficient in blood formation as detectable by the absence of a predetermined marker; and
(b) adding an agent to the population of cells so as to reverse the deficiency. - View Dependent Claims (45, 46, 47, 48, 49, 50, 51)
-
-
52. An assay for determining the activity of a compound capable of modulating hematopoiesis or vascular growth, comprising:
-
(a) selecting a first transgenic animal carrying a marker;
ε
-globin hybrid gene;
wherein the ε
-globin gene is capable of expression at least up to 15.5 dpc.;
(b) mating the first transgenic animal to a second animal that is similarly transgenic;
(c) isolating an embryo from the mating during the gestation period; and
(d) determining the effect of the compound on the stimulation of hematopoiesis and vascular growth in the isolated embryo by measuring marker expression. - View Dependent Claims (53, 54, 55, 56)
-
Specification